Smile T1D
Research type
Research Study
Full title
Semaglutide as an add-on treatment to optimise glycaemic control in children and young people with type 1 diabetes (Smile T1D)
IRAS ID
1008052
Contact name
Timothy Barrett
Contact email
Sponsor organisation
University of Birmingham
Research summary
There is a treatment used for adults with type 2 diabetes, called Semaglutide which is given by an injection under the skin once a week. Semaglutide works by helping people feel full so they eat less and lose weight. This helps people bring down and better control their blood sugar levels.
When given alongside their standard care, we want to find out if Semaglutide can help bring down blood sugar levels in children and young people with Type 1 diabetes (CYPD) so making their diabetes management easier. To do this CYPD whose care is overseen by NHS hospitals will be asked if they want to take part in the study. Those who agree will be divided into two groups; one will continue with their usual treatment whilst the other group will have semaglutide in addition to their usual treatment. We will compare the blood sugar readings from the continuous glucose monitors worn by people in the two groups to see if there is a difference. Members of both groups will be given a test to see if their pancreas is making any C-peptide. Those who are will have this test repeated 26 weeks later to compare how taking semaglutide has affected their pancreatic function.REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
25/LO/0261
Date of REC Opinion
17 Jul 2025
REC opinion
Further Information Favourable Opinion